Hospital EBITDA Impact: India’s Cancer Drug Margin Cap
Hospital EBITDA impact of India’s 30% cancer drug margin cap: the estimate, assumptions to question and key dates, 27 October and 9 November.
Get the latest industry insights and trends in the pharmaceutical sector with Med Pharma News. Stay informed about groundbreaking research, regulatory updates, and market analysis.
Hospital EBITDA impact of India’s 30% cancer drug margin cap: the estimate, assumptions to question and key dates, 27 October and 9 November.
Indian hospital IPOs: Paras Health’s ₹1,450 crore issue, debt-repayment plan, anchor round and expansion, with risks and open questions.
OpenAI life sciences AI adds Orchestra Bio’s R&D coordination team. What Rosalind covers, what was not disclosed and what to watch.
Ebola outbreak Africa update: Nigeria confirms an imported case in Abuja, the fifth country affected. What WHO says and what is still unknown.
GLP-1 beauty market: L’Oréal, Natura and Galderma are testing products for weight-loss skin changes. See the forecasts and open questions.
Biotechnology IPO 2026: Lycia Therapeutics eyes up to $264.6M. What the money funds, the runway and the risks in the filing.
Maharashtra FDA hospital inspection: the Fortis Mulund kitchen suspension and what it means for outsourced hospital services.
Bundibugyo virus outbreak: no approved vaccine or treatment as the DR Congo epidemic reaches an eighth province. What trials are under way.
Labcorp OPKO Health deal: $722M cash plus up to $150M for select BioReference assets. The economics, the logic and what could still change.